PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces New Series of PAR Peptides - AnaSpec has introduced its latest series of PAR peptides
AnaSpec Introduces New Series of PAR Peptides

 

NewswireToday - /newswire/ - San Jose, CA, United States, 2008/07/07 - AnaSpec has introduced its latest series of PAR peptides.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

AnaSpec, one of the world’s largest providers of catalog peptides, has introduced its latest series of PAR peptides.
Protease or Proteinase-Activated Receptors, PARs, belong to the seven transmembrane G-protein coupled family of receptors.1 These receptors are activated when the amino terminus of the receptor is cleaved by specific serine proteases - thrombin (PAR-1, 3 and 4) and trypsin (PAR-2). 2 The cleaved amino end can then act as a tethered ligand on the second extracellular loop of the receptor thereby activating the receptor. 1 Short sequences contained in the amino terminus have been found to activate the receptors on their own, without the need for the protease cleavage.

PAR Peptide Series:
PAR-1 Agonist, STAL – 2, amide
Sequence: SFLLRN-NH2
PAR-1 Agonist, Thrombin Receptor Activator for Peptide 6 (TRAP - 6)
Sequence: SFLLRN
Scrambled PAR-1 Agonist
Sequence: FSLLRN-NH2
Thrombin Receptor (42 - 48) Agonist, human
Sequence: SFLLRNP
Thrombin Receptor Agonist, amide
Sequence: SFLLR-NH2
Thrombin Receptor Agonist
Sequence: SFLLR
Thrombin Receptor Antagonist
Sequence: FLLRN
SFLLRNPNDKYEPF, TRAP-14, Thrombin Receptor 42 - 55, human
Sequence: SFLLRNPNDKYEPF
PAR - 1 Agonist
Sequence: TFLLRN
PAR - 1 Agonist, amide
Sequence: TFLLRN-NH2
PAR - 1 Agonist, amide
Sequence: TFLLRNPNDK-NH2
Protease - Activated Receptor - 2, PAR - 2 Agonist, amide
Sequence: SLIGKV-NH2
PAR - 3 Agonist, amide
Sequence: SFNGGP-NH2
PAR - 1 Agonist, amide
Sequence: TFLLRNPNDK-NH2
Protease - Activated Receptor - 4, PAR - 4 Agonist, amide, human
Sequence: GYPGQV-NH2
Protease - Activated Receptor - 4, PAR - 4 Agonist, amide, murine
Sequence: GYPGKF-NH2
N - 10 Region of TRAP
Sequence: DEIKYSEEVC

About AnaSpec, Inc.
AnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents (dyes, assay kits, & antibodies), and combinatorial chemistry.

References:
1. Macfarlane, SR. et al. Pharmacol. Rev. 53, 245 (2001).
2. Santulli, RJ. et al. PNAS 92, 9151 (1995).

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces New Series of PAR Peptides

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Ping Yang 
408-452-5055 ping[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  Intrinsic Executive Search Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)